Summit Therapeutics (SMMT) Q1 2026 Earnings
SMMT·Reported April 30, 2026·Before market open
Diluted EPS came in at $-0.24 (-166.7% YoY), beat the $-0.33 consensus by $0.09.
Diluted EPS
$-0.24beat by $0.09
Consensus: $-0.33
Financial Snapshot
Trailing eight quarters through Q1 2026
Q1 2026 Earnings FAQ
Common questions about Summit Therapeutics's Q1 2026 earnings report.
Summit Therapeutics (SMMT) reported Q1 2026 earnings on April 30, 2026 before market open.
Summit Therapeutics reported diluted EPS of $-0.24 for Q1 2026.
EPS beat the consensus estimate of $-0.33 by $0.09.
Compared to the same quarter a year prior, diluted EPS declined 166.7% from $-0.09.
You can read the 8-K earnings release (0001599298-26-000037) and the 10-Q periodic report (0001599298-26-000039) directly on SEC EDGAR. The filing index links above go to sec.gov.